prednisone has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 61 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Numerous clinical interventions, including those used to treat multiple sclerosis (MS), have confirmed prednisone (PDN) as a powerful anti-inflammatory drug that reduces the inflammatory response and promotes tissue repair in multiple inflammation sites." | 3.88 | Prednisone alleviates demyelination through regulation of the NLRP3 inflammasome in a C57BL/6 mouse model of cuprizone-induced demyelination. ( Cao, T; Chen, N; Fan, H; Jiang, Z; Lu, G; Wu, M; Yao, R; Yu, H; Zhang, Y, 2018) |
| "We report a patient who developed recurrent acute inflammatory demyelinating polyradiculitis (AIDP) receiving immunosuppressive treatment with cyclosporin and prednisone for secondary chronic graft versus host disease (GVHD) following allogeneic bone marrow transplantation (BMT) from an unrelated donor for chronic myelogenous leukemia (CML)." | 3.69 | Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation. ( Beelen, DW; Liedtke, W; Quabeck, K; Schaefer, UW; Straeten, V, 1994) |
| "Intravenous steroid followed by oral prednisone was administered to patients with Guillain-Barré syndrome (five), acute transverse myelitis (three), and multiple sclerosis in acute relapse (seven)." | 3.66 | Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. ( Bosch, VV; Cook, SD; Dowling, PC, 1980) |
| "Prednisone was shown to cause a small but significant improvement over no treatment in scored neurological disability, some measures of computer-assisted sensory detection threshold, graded muscle strength, and some attributes of nerve conduction." | 2.65 | Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. ( Bartleson, JD; Daube, JR; Dinapoli, RP; Dyck, PJ; Low, PA; Mokri, B; O'Brien, PC; Oviatt, KF; Swift, T; Windebank, AJ, 1982) |
| "Prednisone use was associated with higher mortality [HR = 3." | 1.46 | Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. ( Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017) |
| "In our case, the demyelination was demonstrated by MRI." | 1.35 | Acute demyelinating encephalitis due to Abrus precatorius poisoning--complete recovery after steroid therapy. ( Amalnath, SD; Hamide, A; Narayana, BS; Sahoo, R, 2008) |
| "Electrophysiological studies revealed demyelination in all patients and axonal damage in 94." | 1.30 | [Chronic inflammatory demyelinating polyradiculoneuropathy. Study of 18 cases]. ( Calia, LC; Gabbai, AA; Oliveira, AS, 1997) |
| "Treatment of Hodgkin's disease resulted in complete remission and complete disappearance of the pontine abnormality." | 1.29 | Hodgkin's disease associated with central pontine myelinolysis. ( Carrol, CL; Chintagumpala, MM; Dreyer, ZE; Fishman, MA; Mahoney, DH; McClain, K; Steuber, CP, 1993) |
| "Pain is not usually considered a symptom of chronic relapsing demyelinating polyneuropathy." | 1.29 | Upper limb pain in chronic demyelinating polyneuropathy: electrophysiological correlates. ( Brunet, DG; Zochodne, DW, 1994) |
| "A case of transverse myelopathy in systemic lupus erythematosus with subacute onset and fatal course is reported." | 1.26 | [Transverse myelopathy and systemic lupus erythematosus. Report of a case and review of the literature]. ( Borges, TM; de Macedo, DD; de Mattos, JP, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (34.43) | 18.7374 |
| 1990's | 22 (36.07) | 18.2507 |
| 2000's | 10 (16.39) | 29.6817 |
| 2010's | 7 (11.48) | 24.3611 |
| 2020's | 1 (1.64) | 2.80 |
| Authors | Studies |
|---|---|
| George, IC | 1 |
| Kvalsund, M | 1 |
| Saylor, D | 1 |
| Yu, H | 1 |
| Wu, M | 1 |
| Lu, G | 1 |
| Cao, T | 1 |
| Chen, N | 1 |
| Zhang, Y | 1 |
| Jiang, Z | 1 |
| Fan, H | 1 |
| Yao, R | 1 |
| Ban, BH | 1 |
| Crowe, JL | 1 |
| Iemura, T | 1 |
| Oba, A | 1 |
| Matsui, M | 1 |
| Mano, C | 1 |
| Kawabata, N | 1 |
| Horisawa, Y | 1 |
| Miyahara, Y | 1 |
| Itoh, M | 1 |
| DeVito, N | 1 |
| Mui, K | 1 |
| Jassam, Y | 1 |
| Taylor, L | 1 |
| Pilichowska, M | 1 |
| Cossor, F | 1 |
| Rabah, F | 1 |
| Elmanzalawy, A | 1 |
| Bhuyan, D | 1 |
| El-Banna, N | 1 |
| Beshlawi, I | 1 |
| Villa, A | 1 |
| Quarracino, C | 1 |
| Colobraro, A | 1 |
| D'Haens, G | 1 |
| Reinisch, W | 1 |
| Colombel, JF | 1 |
| Panes, J | 1 |
| Ghosh, S | 1 |
| Prantera, C | 1 |
| Lindgren, S | 1 |
| Hommes, DW | 1 |
| Huang, Z | 1 |
| Boice, J | 1 |
| Huyck, S | 1 |
| Cornillie, F | 1 |
| Sahoo, R | 1 |
| Hamide, A | 1 |
| Amalnath, SD | 1 |
| Narayana, BS | 1 |
| KIBLER, RF | 1 |
| Balcer, LJ | 1 |
| Galetta, SL | 1 |
| Noguchi, M | 1 |
| Yoshita, M | 1 |
| Sakai, K | 1 |
| Matsumoto, Y | 1 |
| Arahata, M | 1 |
| Ontachi, Y | 1 |
| Takami, A | 1 |
| Nakao, S | 1 |
| Sato, K | 1 |
| Yamada, M | 1 |
| Suzuki, C | 1 |
| Tomiyama, M | 1 |
| Baba, M | 1 |
| Jinichi, N | 1 |
| Ogawa, M | 1 |
| Kurahashi, K | 1 |
| Kamijo, M | 1 |
| Couto, M | 1 |
| Conceição, I | 1 |
| de Carvalho, M | 1 |
| Mantadakis, E | 1 |
| Amoiridis, G | 1 |
| Kondi, A | 1 |
| Kalmanti, M | 1 |
| Renard, D | 1 |
| Bonafe, A | 1 |
| Heroum, C | 1 |
| Dowling, PC | 1 |
| Bosch, VV | 1 |
| Cook, SD | 1 |
| Streib, EW | 1 |
| Sun, SF | 1 |
| Dyck, PJ | 3 |
| O'Brien, PC | 1 |
| Oviatt, KF | 1 |
| Dinapoli, RP | 1 |
| Daube, JR | 1 |
| Bartleson, JD | 2 |
| Mokri, B | 1 |
| Swift, T | 1 |
| Low, PA | 2 |
| Windebank, AJ | 1 |
| Aita, JF | 2 |
| Swanson, CJ | 1 |
| Lambert, EH | 1 |
| Krendel, DA | 1 |
| Costigan, DA | 1 |
| Hopkins, LC | 1 |
| Chintagumpala, MM | 1 |
| Mahoney, DH | 1 |
| McClain, K | 1 |
| Dreyer, ZE | 1 |
| Fishman, MA | 1 |
| Carrol, CL | 1 |
| Steuber, CP | 1 |
| Ferrer, X | 1 |
| Vital, C | 1 |
| Larriviere, M | 1 |
| Richard, S | 1 |
| Julien, J | 1 |
| Zochodne, DW | 1 |
| Brunet, DG | 1 |
| Nemni, R | 1 |
| Amadio, S | 1 |
| Fazio, R | 1 |
| Galardi, G | 1 |
| Previtali, S | 1 |
| Comi, G | 1 |
| Liedtke, W | 1 |
| Quabeck, K | 1 |
| Beelen, DW | 1 |
| Straeten, V | 1 |
| Schaefer, UW | 1 |
| Pareyson, D | 1 |
| Ciano, C | 1 |
| Fiacchino, F | 1 |
| Gemma, M | 1 |
| Savoiardo, M | 1 |
| Sghirlanzoni, A | 1 |
| Beck, RW | 1 |
| Kupersmith, MJ | 1 |
| Cleary, PA | 1 |
| Katz, B | 1 |
| Uncini, A | 2 |
| Sabatelli, M | 1 |
| Mignogna, T | 1 |
| Lugaresi, A | 3 |
| Liguori, R | 2 |
| Montagna, P | 2 |
| Mahattanakul, W | 1 |
| Crawford, TO | 1 |
| Griffin, JW | 1 |
| Goldstein, JM | 1 |
| Cornblath, DR | 1 |
| Van Doorn, PA | 2 |
| van der Meché, FG | 1 |
| Gorson, KC | 1 |
| Allam, G | 1 |
| Ropper, AH | 1 |
| Simmons, Z | 1 |
| Wald, JJ | 1 |
| Albers, JW | 1 |
| Calia, LC | 1 |
| Oliveira, AS | 1 |
| Gabbai, AA | 1 |
| Rizzi, R | 1 |
| Vetrugno, R | 1 |
| Salvi, F | 1 |
| Cevoli, S | 1 |
| De Luca, G | 1 |
| Iarlori, C | 1 |
| Marzoli, F | 1 |
| Di Iorio, A | 1 |
| Gambi, D | 1 |
| Dumas, JL | 1 |
| Valeyre, D | 1 |
| Chapelon-Abric, C | 1 |
| Belin, C | 1 |
| Piette, JC | 1 |
| Tandjaoui-Lambiotte, H | 1 |
| Brauner, M | 1 |
| Goldlust, D | 1 |
| Gekht, BM | 1 |
| Kasatkina, LF | 1 |
| Merkulova, DM | 1 |
| Samoĭlov, MI | 1 |
| Katz, JS | 1 |
| Barohn, RJ | 1 |
| Kojan, S | 1 |
| Wolfe, GI | 1 |
| Nations, SP | 1 |
| Saperstein, DS | 1 |
| Amato, AA | 1 |
| de Macedo, DD | 1 |
| de Mattos, JP | 1 |
| Borges, TM | 1 |
| Oh, SJ | 2 |
| Joy, JL | 1 |
| Sunwoo, I | 1 |
| Kuruoglu, R | 1 |
| Bird, SJ | 1 |
| Sladky, JT | 2 |
| Gil-Néciga, E | 1 |
| Alberca, R | 1 |
| Madrazo, J | 1 |
| Chinchón, I | 1 |
| Muñoz-Málaga, A | 1 |
| Jakobsen, J | 1 |
| Krarup, C | 1 |
| Urval, K | 1 |
| Nelson, RP | 1 |
| Cohen, SR | 1 |
| Good, RA | 1 |
| Fillyaw, MJ | 1 |
| Tandan, R | 1 |
| Bradley, WG | 1 |
| Ruderman, MI | 1 |
| Turkewitz, LJ | 1 |
| Brown, MJ | 1 |
| Berman, PH | 1 |
| Wertman, E | 1 |
| Argov, Z | 1 |
| Abrmasky, O | 1 |
| Garbern, J | 1 |
| Spence, AM | 1 |
| Alvord, EC | 1 |
| Kiprov, DD | 1 |
| Miller, RG | 1 |
| O'Brien, P | 1 |
| Swanson, C | 1 |
| Low, P | 1 |
| Daube, J | 1 |
| Snyder, DH | 1 |
| Reichl, W | 1 |
| Basu, DB | 1 |
| Gilroy, J | 1 |
| Meyer, JS | 1 |
| DeVivo, DC | 1 |
| Engel, WK | 1 |
| Schneck, SA | 1 |
| Gumbinas, M | 1 |
| Oda, M | 1 |
| Huttenlocher, P | 1 |
| Manz, HJ | 1 |
| Dinsdale, HB | 1 |
| Morrin, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy[NCT00705614] | 2,662 participants (Actual) | Observational | 2003-07-31 | Completed | |||
| InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy[NCT04529291] | 0 participants (Actual) | Interventional | 2022-04-16 | Withdrawn (stopped due to The IP decided to stop.) | |||
| [NCT00000147] | 0 participants | Interventional | 1988-07-31 | Active, not recruiting | |||
| [NCT00000146] | Phase 3 | 0 participants | Interventional | 1988-07-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participant fatalities was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 30 |
| Standard Therapy | 14 |
| Switched to Remicade | 4 |
The number of participants with demyelinating neurological disorders was evaluated. Demyelinating neurological disorders were defined as multiple sclerosis, optic neuritis, peripheral syndromes such as peripheral neuropathy, mononeuropathy multipex, cranial neuropathies, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and transverse myelitis. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 4 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants wtih hematologic conditions was evaluated. A hematologic condition was defined as thrombocytopenia, neutropenia, pancytopenia, granulocytopenia, leukopenia, or aplastic anemia. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 50 |
| Standard Therapy | 11 |
| Switched to Remicade | 7 |
The number of participants with infusion-related reactions and/or hypersensitivity was evaluated. An infuson-related reaction/hypersensitivity was defined as as an acute reaction, including anaphylactic shock that occurs after the onset of the infusion or within the 1- to 2-hour observation period following the end of the infusion. Delayed hypersensitivity reactions (myalgia and/or arthralgia with fever and rash within 14 days of the infusion) were included. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 173 |
| Standard Therapy | 1 |
| Switched to Remicade | 28 |
The number of participants wtih lymphoproliferative disorders and/or malignancies was evaluated. A lymphoproliferative disorder and /or malignancy included, but was not limited to, lymphoma, gastrointestinal cancer, skin cancer (including basocellular and squamous carcinoma, melanoma) and in situ cervical carcinoma. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 49 |
| Standard Therapy | 21 |
| Switched to Remicade | 8 |
The number of participants with new or worsening congestive heart failure was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 1 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants experiencing serious infections was evaluated. Serious infections included, but were not limited to, tuberculosis, opportunistic infections (such as Pneumocystis carinii [PCP] pneumonia, listeriosis, atypical mycobacteria, and histoplasmosis), salmonellosis,and serious viral infections. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 132 |
| Standard Therapy | 47 |
| Switched to Remicade | 18 |
The duration of hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Days (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=657,418 ,0) | Visit 2 (n=304,126, 33) | Visit 3 (n=216, 58, 35) | Visit 4 (n=151, 60, 24) | Visit 5 (n=105, 35, 34) | Visit 6 (n=107, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=80, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 12.2 | 14.4 | 14.2 | 12.6 | 11.7 | 10.8 | 10.6 | 9.5 | 12.4 | 10.1 | 11.4 |
| Standard Therapy | 10.8 | 12.0 | 9.4 | 8.5 | 9.8 | 13.7 | 10.2 | 16.3 | 6.9 | 8.0 | 8.7 |
| Switched to Remicade | NA | 13.0 | 13.5 | 9.1 | 7.1 | 18.3 | 10.0 | 14.7 | 10.7 | 9.0 | 18.1 |
The number of participant hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Hospital Stays (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1539, 1121, 0) | Visit 2 (n=1418, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1170, 665, 208) | Visit 7 (n=1111, 615, 219) | Visit 8 (n=1099, 589, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1031, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 0.7 | 0.3 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Standard Therapy | 0.5 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Switched to Remicade | NA | 0.5 | 0.4 | 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
The number of participants undergoing surgical procedures for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Surgical Procedures (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Basline; n=660, 419, 0) | Visit 2 (n=304, 126, 33) | Visit 3 (n=217, 57, 36) | Visit 4 (n=153, 60, 24) | Visit 5 (n=106, 36, 34) | Visit 6 (n=108, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=82, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 171 | 135 | 121 | 68 | 50 | 49 | 48 | 43 | 38 | 38 | 34 |
| Standard Therapy | 81 | 51 | 23 | 16 | 14 | 21 | 20 | 12 | 13 | 13 | 6 |
| Switched to Remicade | NA | 7 | 12 | 8 | 14 | 11 | 6 | 7 | 8 | 8 | 8 |
The number of participants with a draining fistula was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1541, 1120, 0) | Visit 2 (n=1420, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1169, 666, 208) | Visit 7 (n=1110, 615, 219) | Visit 8 (n=1097, 588, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1030, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 349 | 211 | 170 | 146 | 125 | 114 | 97 | 105 | 98 | 85 | 87 |
| Standard Therapy | 96 | 51 | 41 | 31 | 29 | 26 | 31 | 23 | 32 | 15 | 16 |
| Switched to Remicade | NA | 16 | 19 | 12 | 15 | 15 | 15 | 16 | 15 | 20 | 20 |
The participant assessment of overall health status was evaluated at baseline and each study visit. The overall health status questionnaire asked participants to rate their current health status over the prior 24 hours as 1=best possible, 2=much better than average, 3=better than average, 4=average, 5=worse than average, 6=much worse than average, or 7=worst possible. Scores ranged from 1 to 7 with lower scores indicating better health status. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1526, 1116, 0) | Visit 2 (n=1344, 903, 95) | Visit 3 (n=1280, 809, 146) | Visit 4 (n=1217, 755, 162) | Visit 5 (n=1160, 704, 184) | Visit 6 (n=1110, 649, 202) | Visit 7 (n=1046, 606, 212) | Visit 8 (n=1044, 573, 221) | Visit 9 (n=999, 544, 223) | Visit 10 (n=963, 520, 227) | Visit 11 (n=956, 527, 235) | |
| Remicade | 4.3 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.0 | 3.0 |
| Standard Therapy | 3.9 | 3.3 | 3.1 | 3.0 | 3.1 | 3.0 | 3.0 | 3.0 | 2.9 | 2.8 | 2.8 |
| Switched to Remicade | NA | 3.9 | 3.6 | 3.5 | 3.2 | 3.4 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 |
The Harvey-Bradshaw Index of Crohn's Disease Acitivity was evaluated at each study visit. The Harvey-Bradshaw Index evaluates participants' general health in the day prior in the domains of well being, abdominal pain, number of liquid stools per day, and abdominal mass and complications and was evaluated on the day of the study visit. The score is derived from a 0-4 score for general well being, 0-3 for abdmonial pain, raw score for number of liquid stools per day, 0-3 for abdominal mass, and raw score for complications. The total score is from 0 to infinity, with lower scores indicating better outcomes. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1505, 1106, 0) | Visit 2 (n=1320, 876, 91) | Visit 3 (n=1250, 785, 143) | Visit 4 (n=1196, 742, 159) | Visit 5 (n=1127, 692, 181) | Visit 6 (n=1070, 647, 199) | Visit 7 (n=1023, 592, 209) | Visit 8 (n=1015, 562, 224) | Visit 9 (n=953, 546, 219) | Visit 10 (n=936, 526, 225) | Visit 11 (n=918, 525, 238) | |
| Remicade | 8.2 | 4.1 | 3.7 | 3.8 | 3.7 | 3.6 | 3.6 | 3.6 | 3.6 | 3.4 | 3.4 |
| Standard Therapy | 6.2 | 3.8 | 3.5 | 3.2 | 3.4 | 3.1 | 3.0 | 3.2 | 2.9 | 2.7 | 2.7 |
| Switched to Remicade | NA | 6.0 | 4.4 | 4.8 | 4.9 | 4.5 | 4.1 | 4.1 | 4.4 | 4.3 | 4.2 |
The participant work/daily activity status score was evaluated at each study visit. The work/daily activity questionnaire asked participants to rate their level of daily functioning on a scale of 1 to 10 with a lower score indicating less of an impact of Crohn's disease on work or daily life functioning. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1496, 1108, 0) | Visit 2 (n=1316, 895, 94) | Visit 3 (n=1235, 797, 143) | Visit 4 (n=1192, 738, 159) | Visit 5 (n=1128, 694, 179) | Visit 6 (n=1077, 638, 201) | Visit 7 (n=1030, 601, 207) | Visit 8 (n=1025, 571, 221) | Visit 9 (n=982, 542, 222) | Visit 10 (n=934, 514, 225) | Visit 11 (n=925, 521, 235) | |
| Remicade | 5.9 | 4.2 | 3.8 | 3.6 | 3.4 | 3.3 | 3.2 | 3.3 | 3.3 | 3.1 | 3.2 |
| Standard Therapy | 4.9 | 3.7 | 3.2 | 2.9 | 3.0 | 2.7 | 2.8 | 2.7 | 2.6 | 2.4 | 2.4 |
| Switched to Remicade | NA | 5.5 | 4.8 | 4.3 | 4.0 | 3.9 | 3.6 | 3.5 | 3.5 | 3.6 | 3.6 |
3 reviews available for prednisone and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Treatment of acute demyelinating optic neuritis.
Topics: Acute Disease; Clinical Trials as Topic; Demyelinating Diseases; Humans; Infusions, Intravenous; Int | 2002 |
Treatment of patients with chronic inflammatory demyelinating polyneuropathy.
Topics: Anti-Inflammatory Agents; Chronic Disease; Demyelinating Diseases; Humans; Immunoglobulins, Intraven | 1996 |
Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.
Topics: Adult; Aged; Antigens, Bacterial; Autoantigens; Autoimmune Diseases; Campylobacter; Campylobacter In | 1995 |
4 trials available for prednisone and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment.
Topics: Adolescent; Adult; Chronic Disease; Clinical Trials as Topic; Demyelinating Diseases; Female; Humans | 1982 |
Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Color Vision Defects; Contrast Sensitivity; Demyel | 1993 |
Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Color Vision Defects; Contrast Sensitivity; Demyel | 1993 |
Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Color Vision Defects; Contrast Sensitivity; Demyel | 1993 |
Fellow eye abnormalities in acute unilateral optic neuritis. Experience of the optic neuritis treatment trial.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Color Vision Defects; Contrast Sensitivity; Demyel | 1993 |
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Child; Chronic Disease; Combined Modality Therapy | 1999 |
Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy.
Topics: Adult; Aged; Azathioprine; Demyelinating Diseases; Drug Combinations; Female; Humans; Male; Middle A | 1985 |
54 other studies available for prednisone and Clinically Isolated CNS Demyelinating Syndrome
| Article | Year |
|---|---|
A case of combined central and peripheral demyelination in Zambia.
Topics: Adult; Azathioprine; Comorbidity; Demyelinating Diseases; Developing Countries; Glucocorticoids; Hum | 2020 |
Prednisone alleviates demyelination through regulation of the NLRP3 inflammasome in a C57BL/6 mouse model of cuprizone-induced demyelination.
Topics: Animals; Astrocytes; Corpus Callosum; Cuprizone; Cytokines; Demyelinating Diseases; Disease Models, | 2018 |
Oculomotor Nerve Demyelination Secondary to Certolizumab Pegol.
Topics: Adult; Antirheumatic Agents; Arthritis, Psoriatic; Certolizumab Pegol; Demyelinating Diseases; Diagn | 2018 |
Substantial Improvement in a Nerve Conduction Study of Lymphoma-associated Demyelinating Neuropathy Treated by Intravenous Immunoglobulin and Chemotherapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2018 |
Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy | 2014 |
A Demyelinating Disease; What Lies Beneath?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms; Child, Pres | 2016 |
Pseudotumoral lesion: pathology and follow-up.
Topics: Adult; Anti-Inflammatory Agents; Brain Diseases; Demyelinating Diseases; Female; Follow-Up Studies; | 2016 |
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azathio | 2017 |
Acute demyelinating encephalitis due to Abrus precatorius poisoning--complete recovery after steroid therapy.
Topics: Abrin; Abrus; Acute Disease; Administration, Oral; Demyelinating Diseases; Encephalitis; Glucocortic | 2008 |
LARGE DOSE CORTICOSTEROID THERAPY OF EXPERIMENTAL AND HUMAN DEMYELINATING DISEASES.
Topics: Adrenal Cortex Hormones; Animals; Demyelinating Diseases; Drug Therapy; Encephalomyelitis; Encephalo | 1965 |
Peripheral neuropathy associated with chronic natural killer cell lymphocytosis.
Topics: Action Potentials; Aged; Anti-Inflammatory Agents; Demyelinating Diseases; Female; Humans; Killer Ce | 2005 |
Reversible multifocal conduction block in sarcoid neuropathy.
Topics: Aged; Anti-Inflammatory Agents; Demyelinating Diseases; Dermatitis; Electromyography; Female; Humans | 2006 |
Steroid-responsive demyelinating motor neuropathy with conduction block associated with hepatitis C infection and treatment with interferon alpha.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Demyelinating Diseases; Evoked Potentials, Somatosensory | 2006 |
Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia.
Topics: Adult; Antifungal Agents; Antineoplastic Agents; Demyelinating Diseases; Electromyography; Fever; Hu | 2007 |
Transient lesion in the splenium of the corpus callosum after oral corticoid therapy.
Topics: Administration, Oral; Anti-Inflammatory Agents; Arginine Vasopressin; Confusion; Corpus Callosum; De | 2007 |
Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis.
Topics: Acute Disease; Adolescent; Adrenocorticotropic Hormone; Adult; Demyelinating Diseases; Dose-Response | 1980 |
Acquired demyelinative polyneuropathy: diagnosis and treatment with special reference to immunosuppressive therapy.
Topics: Adult; Azathioprine; Demyelinating Diseases; Female; Humans; Immunosuppressive Agents; Male; Middle | 1984 |
Atypical contrast enhancement in computed tomography of demyelinating disease.
Topics: Blood-Brain Barrier; Demyelinating Diseases; Dexamethasone; Humans; Multiple Sclerosis; Prednisone; | 1982 |
Prednisone-responsive hereditary motor and sensory neuropathy.
Topics: Adolescent; Adult; Axons; Cerebrospinal Fluid Proteins; Charcot-Marie-Tooth Disease; Demyelinating D | 1982 |
Successful treatment of neuropathies in patients with diabetes mellitus.
Topics: Aged; Azathioprine; Cyclophosphamide; Demyelinating Diseases; Diabetes Mellitus, Type 1; Diabetes Me | 1995 |
Hodgkin's disease associated with central pontine myelinolysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Dacarbazine; Demyelinating Disease | 1993 |
Idiopathic CD4+ T-cell lymphocytopenia and subacute inflammatory demyelinating polyradiculoneuropathy.
Topics: Anemia, Hemolytic; Arthralgia; CD4-Positive T-Lymphocytes; Demyelinating Diseases; Electrophysiology | 1995 |
Upper limb pain in chronic demyelinating polyneuropathy: electrophysiological correlates.
Topics: Arm; Demyelinating Diseases; Electric Stimulation; Female; Humans; Leg; Male; Middle Aged; Neurologi | 1994 |
Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments.
Topics: Adult; Demyelinating Diseases; Female; Humans; Immunoglobulins, Intravenous; Male; Middle Aged; Neur | 1994 |
Recurrent acute inflammatory demyelinating polyradiculitis after allogeneic bone marrow transplantation.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Chronic Disease; Cyclosporine; Demyelinating Dise | 1994 |
Combined central and peripheral acute demyelination.
Topics: Adult; Brain; Central Nervous System Diseases; Demyelinating Diseases; Electroencephalography; Elect | 1993 |
Chronic progressive steroid responsive axonal polyneuropathy: a CIDP vaariant or a primary axonal disorder?
Topics: Adolescent; Adult; Aged; Axons; Biopsy; Chronic Disease; Demyelinating Diseases; Diagnosis, Differen | 1996 |
Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.
Topics: Adolescent; Adult; Aged; Cyclosporine; Demyelinating Diseases; Female; Humans; Inflammation; Male; M | 1996 |
Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Demyelinating Diseases; Female; | 1997 |
Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults.
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Demyelinating Diseases; Female; Follow- | 1997 |
[Chronic inflammatory demyelinating polyradiculoneuropathy. Study of 18 cases].
Topics: Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Demyelinating Diseases; Female; Fluorescent | 1997 |
Steroid-responsive multifocal demyelinating neuropathy with central involvement.
Topics: Adult; Central Nervous System Diseases; Demyelinating Diseases; Electrodiagnosis; Evoked Potentials, | 1999 |
Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy.
Topics: Adult; Brain; Brain Diseases; Contrast Media; Demyelinating Diseases; Disease Progression; Female; F | 2000 |
[The role of clinical investigations in the study of mechanisms of development of acquired demyelinating polyneuropathies].
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Demyelinating Diseases; Humans; Male; Myelin Sheath; Po | 2000 |
Axonal multifocal motor neuropathy without conduction block or other features of demyelination.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Axons; Demyelinating Diseases; Electromyography; | 2002 |
[Transverse myelopathy and systemic lupus erythematosus. Report of a case and review of the literature].
Topics: Adolescent; Demyelinating Diseases; Dexamethasone; Drug Therapy, Combination; Female; Humans; Hydrox | 1979 |
Subacute demyelinating polyneuropathy responding to corticosteroid treatment.
Topics: Adult; Biopsy; Cerebrospinal Fluid Proteins; Child; Demyelinating Diseases; Disability Evaluation; E | 1978 |
A case of chronic sensory demyelinating neuropathy responding to immunotherapies.
Topics: Azathioprine; Demyelinating Diseases; Humans; Immunotherapy; Male; Middle Aged; Nervous System Disea | 1992 |
Corticosteroid-responsive dominantly inherited neuropathy in childhood.
Topics: Child; Child, Preschool; Demyelinating Diseases; Electrodiagnosis; Female; Genes, Dominant; Humans; | 1991 |
[Multifocal demyelinating neuropathy with persistent conduction blocks and continuous muscular activity].
Topics: Adult; Carbamazepine; Combined Modality Therapy; Demyelinating Diseases; Fasciculation; Female; Huma | 1991 |
[Immunomodulator therapy of chronic inflammatory demyelinating polyradiculoneuropathy].
Topics: Adjuvants, Immunologic; Adult; Azathioprine; Chronic Disease; Demyelinating Diseases; Female; Humans | 1991 |
Intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy recalcitrant to conventional therapy.
Topics: Chronic Disease; Demyelinating Diseases; Drug Resistance; Humans; Immunoglobulins, Intravenous; Male | 1991 |
Serial evaluation of neuromuscular function in management of chronic inflammatory demyelinating polyneuropathy. A case report.
Topics: Activities of Daily Living; Adult; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Dem | 1987 |
Current therapy of demyelinating neuropathies.
Topics: Adrenocorticotropic Hormone; Adult; Charcot-Marie-Tooth Disease; Child; Chronic Disease; Combined Mo | 1985 |
Chronic inflammatory demyelinating polyneuropathy of infancy: a corticosteroid-responsive disorder.
Topics: Child, Preschool; Demyelinating Diseases; Female; Humans; Infant; Infant, Newborn; Male; Neural Cond | 1986 |
Chronic inflammatory demyelinating polyradiculoneuropathy: features and prognostic factors with corticosteroid therapy.
Topics: Action Potentials; Adult; Demyelinating Diseases; Dose-Response Relationship, Drug; Female; Follow-U | 1988 |
Balo's concentric demyelination diagnosed premortem.
Topics: Adult; Biopsy, Needle; Brain; Demyelinating Diseases; Diffuse Cerebral Sclerosis of Schilder; Hemipl | 1986 |
Paraproteinemia associated with demyelinating polyneuropathy or myositis: treatment with plasmapheresis and immunosuppressive drugs.
Topics: Azathioprine; Cyclophosphamide; Demyelinating Diseases; Female; Humans; Immunosuppressive Agents; Ma | 1985 |
Myasthenia gravis and multiple sclerosis: an unusual combination of diseases.
Topics: Adult; Brain; Demyelinating Diseases; Diplopia; Edrophonium; Electroencephalography; Female; gamma-G | 1974 |
Intermittent corticosteroid treatment of demyelinating diseases in childhood.
Topics: Adrenocorticotropic Hormone; Adult; Child; Demyelinating Diseases; Diffuse Cerebral Sclerosis of Sch | 1968 |
Remarkable recovery of a steroid-responsive recurrent polyneuropathy.
Topics: Biopsy; Child; Chloroquine; Demyelinating Diseases; Electromyography; Female; Humans; Locomotion; Mu | 1970 |
Neurology and neuropathology of immunosuppressive therapy and acquired immunological deficiency.
Topics: Adolescent; Adult; Agammaglobulinemia; Aspergillus; Azathioprine; Brain; Brain Diseases; Candida; Ce | 1971 |
The effects of corticosteroids on myelination of the developing rat brain.
Topics: Adrenal Cortex Hormones; Animals; Axons; Brain; Demyelinating Diseases; Humans; Infant, Newborn; Inf | 1973 |
Progressive multifocal leukoencephalopathy after renal transplantation. Demonstration of Papova-like virions.
Topics: Adult; Autopsy; Azathioprine; Brain; Demyelinating Diseases; Encephalitis; Female; Gliosis; Humans; | 1971 |